IceCure任命Meir Peleg为首席财务官

2026-03-24 21:01

IceCure Medical (ICCM) announced on Tuesday the appointment of Meir Peleg as its chief financial officer, effective May 17, 2026.
In addition, IceCure plans to appoint Richard E. Fine in the second quarter of 2026 as the company's medical director to lead breast indications. In this role, Fine will support IceCure's clinical and educational initiatives in breast cryoablation, including the company's previously announced FDA-approved ChoICE post-marketing study evaluating ProSense® cryoablation for the treatment of low-risk breast cancer.
In alignment with IceCure's corporate strategy and technological roadmap, the company has initiated a search for a new chief technology officer. Naum Muchnik, IceCure's Vice President of R&D and Engineering, will be departing his role effective April 12, 2026. IceCure thanks Mr. Muchnik for his contributions during his tenure.
ICCM +5.08% premarket to $0.6699.
Source: Press Release

More on IceCure Medical